✦ LIBER ✦

Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia

✍ Scribed by J. Björkander; J. Nikoskelainen; H. Leibl; P. Lanbeck; J. Wallvik; J. T. Lumio; J. H. Braconier; B. G. Pavlova; K. Birthistle; W. Engl; S. Walter; H. J. Ehrlich

Book ID: 110912778
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 116 KB
Volume: 90
Category: Article
ISSN: 0042-9007
DOI: 10.1111/j.1423-0410.2006.00764.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, Efficacy and Pharmacokinetics of

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

✍ Wasserman, Richard L.; Church, Joseph A.; Stein, Mark; Moy, James; White, Martha 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 154 KB

Safety, efficacy, tolerability, and phar

Safety, efficacy, tolerability, and pharmacokinetics of a new liquid intravenous immunoglobulin (IVIG) in comparison to Sandoglobulin® in patients with primary immunodeficiencies (PID)

✍ Borte, M.; Wahn, U.; Farber, C.; Bernatowska, E.; Adams, C.; Andresen, I.; Bende 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 130 KB

A multicenter, open-label, efficacy, pha

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis

✍ Shigeto Kobayashi,Masayoshi Harigai,Neelufar Mozaffarian… 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 261 KB

Safety and Efficacy of Privigen®, a Nove

Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

✍ Mark R. Stein; Robert P. Nelson; Joseph A. Church; Richard L. Wasserman; Michael 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 166 KB

Efficacy, Safety and Tolerability of a N

Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency

✍ Joseph A. Church; Heinz Leibl; Mark R. Stein; Isaac R. Melamed; Arye Rubinstein; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 443 KB

A Prospective, Open-Label Safety and Eff

A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma

✍ Yang, Hank H.; Vescio, Robert; Schenkein, David; Berenson, James R. 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 129 KB